Dear Pancreatobiliary Pathology Society Members,
Neoadjuvant therapy is increasingly used for the treatment of pancreatic cancer. Resection specimens that have undergone such treatment pose substantial diagnostic, staging, prognostic and reporting challenges. These issues have been raised at past PBPS meetings as some of the more challenging areas in our field that require further standardization.
In order to address this, PBPS has created a new working group, the Neo-Adjuvant Therapy Working Group, whose role will be to tackle these issues. After reviewing the many highly qualified applicants for membership, we selected the following new members and look forward to learning from them.
- Dr. Runjan Chetty from Toronto General Hospital, Canada
- Dr. Huamin Wang from MD Anderson Cancer Center, USA
- Daniela Allende from Cleveland Clinic, USA
- Dr. Irene Esposito from Heinrich-Heine University of Duesseldorf, Germany
- Dr. Mojgan Hosseini from University of California San Diego, USA
- Dr. Yoko Matsuda from Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Japan
Pancreatobiliary Pathology Society Education Committee